Novel Flow Cytometry-Based Method for Detection of Anti-HLA Complement Activating Donor-Specific Antibodies in Renal Transplant Recipients and Its Comparison With Other Conventional Detection Methods

被引：1

作者：

Rani, Lekha ^{[1
]}

Singh, Heera ^{[1
]}

Saikia, Biman ^{[1
]}

Aggarwal, Ritu ^{[1
]}

Kumar, Yashwant ^{[1
]}

Kumar, Mahendra ^{[1
]}

Chhabra, Seema ^{[1
]}

Kumar, Manoj ^{[2
]}

Kumar, Bhuvnesh ^{[2
]}

Kumar, Vinkesh ^{[2
]}

Das, Prabir ^{[1
]}

Sharma, Ashish ^{[2
]}

Ramchandran, Raja ^{[3
]}

Kohli, Harbir Singh ^{[3
]}

Minz, Ranjana Walker ^{[1
,4
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Immunopathol, Chandigarh 160012, India

[2] Postgrad Inst Med Educ & Res, Dept Renal Transplant Surg, Chandigarh, India

[3] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh, India

[4] Post Grad Inst Med Educ & Res, Dept Immunopathol, Chandigarh 160012, India

来源：

TRANSPLANTATION PROCEEDINGS | 2023年 / 55卷 / 01期

关键词：

CROSS-MATCH; CYTOTOXICITY;

D O I：

10.1016/j.transproceed.2022.11.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background. Presence of preformed donor specific antibodies (DSAs) detected by complement-dependent cytotoxicity (CDC-XM) is a strong contraindication for transplant. However, it has limitations including its sensitivity and its inability to distinguish between HLA-specific and other non-HLA-specific antibodies. In this study, we standardized CDC-XM by flow cytometry and determined its relevance by comparing its results with other methods of DSA detection, such as routine CDC-XM, antibody binding assay by flow cytometry (FC-XM), and Luminex-based crossmatch assays, such as Luminex crossmatch (LXM) and virtual crossmatch (VXM).Materials and Methods. A total of 79 serum samples were tested for DSAs by the flow cytometric complement-dependent cytotoxicity crossmatch assay (FC-CDC-XM) and then the results of FC-CDC-XM were compared with other detection methods such as CDC-XM, FC-XM, LXM, and VXM.Results. We found that the FC-CDC-XM assay is more sensitive than routine CDC-XM. Out of total 79 sera, 24 sera were detected positive (T cells positive: 1 case and B cells positive: 23) by FC-CDC-XM as compared with 3 sera using CDC-XM; these 3 sera also showed positivity by FC-CDC-XM. After FC-XM assay, 23 samples were positive by FC-XM and out of these 23 samples, 13 were also positive by FC-CDC-XM. On comparing the FC-CDC-XM results with VXM and LXM, 10 sera of 24 FC-CDC-XM positive had HLA class II antibodies detected on aConclusions. The FC-CDC-XM is a more sensitive and specific method for detection of HLA-specific complement-fixing antibodies than CDC-XM and FC-XM. FC-CDC-XM should be used in tissue-typing laboratories after intra- and inter- laboratory validation.

引用

页码：134 / 139

页数：6

共 37 条

[31] Prevalence of Donor-Specific Anti-HLA Antibodies and C4 d Deposits in Pediatric Renal Transplant Recipients: Serological / histological Correlations and Impact On Graft Function and Survival.
Monteverde, M.
Chaparro, A.
Balbarrey, Z.
Marcos, Y.
Padros, K.
Goldberg, J.
Briones, L.
Rush, D.
TRANSPLANTATION, 2014, 98 : 501 - 501
[32] Clinical Implication of Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients: Do We Really Have to Care All the DSA Positive Patients?
Sato, T.
Seguchi, O.
Kanaumi, Y.
Yanase, M.
Okada, N.
Kuroda, K.
Hisamatsu, E.
Sunami, H.
Nakajima, S.
Hata, H.
Fujita, T.
Ishibashi-Ueda, H.
Fukushima, N.
Kobayashi, J.
Nakatani, T.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S208 - S208
[33] Association of Circulating Anti-HLA Donor-Specific Antibodies and Their Characteristics, including C1q-Binding Capacity, in Kidney Transplant Recipients with Long-Term Renal Graft Outcomes
Gniewkiewicz, Michal
Czerwinska, Katarzyna
Zielniok, Katarzyna
Durlik, Magdalena
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
[34] Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies
Arnold, Marie-Luise
Ntokou, Irma-Sofia
Doxiadis, Ilias I. . N.
Spriewald, Bernd M.
Boletis, John N.
Iniotaki, Aliki G.
TRANSPLANT INTERNATIONAL, 2014, 27 (03) : 253 - 261
[35] COMPARISON OF TWO LUMINEX SINGLE-ANTIGEN BEAD FLOW CYTOMETRY ASSAYS FOR DETECTION OF DE NOVO DONOR-SPECIFIC ANTIBODIES FOR THE DIAGNOSIS OF SUBCLINICAL ABMR AFTER RENAL TRANSPLANTATION
Bertrand, D.
Kaveri, R.
Jaureguy, M.
Gatault, P.
Garrouste, C.
Sayegh, J.
Bouvier, N.
Caillard, S.
Lanfranco, L.
Galinier, A.
Etienne, I.
Ois, A. Franc
Hau, F.
Farce, F.
TRANSPLANT INTERNATIONAL, 2020, 33 : 20 - 20
[36] COMPARISON OF TWO LUMINEX SINGLE-ANTIGEN BEAD FLOW CYTOMETRY ASSAYS FOR DETECTION OF HLA CLASS I AND CLASS II DONOR SPECIFIC ANTIBODIES AFTER RENAL TRANSPLANTATION
Farce, Fabienne
Bertrand, Dominique
Etienne, Isabelle
Laurent, Charlotte
Francois, Arnaud
Guerrot, Dominique
Hau, Francoise
HLA, 2016, 87 (04) : 241 - 241
[37] From lymphocytotoxicity to flow cytometry based donor specific antibody testing on the Luminex platform : developing a cost effective and efficient algorithm for detection of anti HLA antibodies in the Indian scenario
Daniel, D.
Chacko, P.
Shanthi, R.
John, G.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2008, 30 : 108 - 108

← 1 2 3 4 →